Cisplatin-DNA damage recognition proteins in human tumour extracts.

por Bissett, D., McLaughlin, K., Kelland, L. R., Brown, R.
Publicado 1993

Phase I and pharmacokinetic study of D-verapamil and doxorubicin.

por Bissett, D., Kerr, D. J., Cassidy, J., Meredith, P., Traugott, U., Kaye, S. B.
Publicado 1991

First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action

por Verborg, W, Thomas, H, Bissett, D, Waterfall, J, Steiner, J, Cooper, M, Rankin, E M
Publicado 2007

Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.

por Bissett, D., Jodrell, D., Harnett, A. N., Habeshaw, T., Kaye, S. B., Evans, D., Williams, M., Canney, P. A.
Publicado 1995

Long-term sequelae of treatment for testicular germ cell tumours.

por Bissett, D., Kunkeler, L., Zwanenburg, L., Paul, J., Gray, C., Swan, I. R., Kerr, D. J., Kaye, S. B.
Publicado 1990

Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034

por Bissett, D, McLeod, H L, Sheedy, B, Collier, M, Pithavala, Y, Paradiso, L, Pitsiladis, M, Cassidy, J
Publicado 2001

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

por Bissett, D, Cassidy, J, de Bono, J S, Muirhead, F, Main, M, Robson, L, Fraier, D, Magnè, M L, Pellizzoni, C, Porro, M G, Spinelli, R, Speed, W, Twelves, C
Publicado 2004